about
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonistsAdenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directionsPast, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Late-onset Parkinsonism in NFκB/c-Rel-deficient miceHow reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence.Novel investigational adenosine A2A receptor antagonists for Parkinson's disease.Pharmacological therapy of Parkinson's disease: current options and new avenues.A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice.Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats.Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation.Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats.Subchronic caffeine exposure induces sensitization to caffeine and cross-sensitization to amphetamine ipsilateral turning behavior independent from dopamine release.Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata.L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration.Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment.New adenosine A2A receptor antagonists: actions on Parkinson's disease models.Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D(1) but not D(2) receptor agonists.Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia.Antidepressants and atypical neuroleptics induce Fos-like immunoreactivity in the central extended amygdala.Differential induction of Fos-like-immunoreactivity in the extended amygdala after haloperidol and clozapine.Stimulation of dopamine transmission in the dorsal caudate nucleus by pargyline as demonstrated by dopamine and acetylcholine microdialysis and Fos immunohistochemistry.Induction of Fos-like-immunoreactivity in the central extended amygdala by antidepressant drugs.Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol.Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses.Combined microdialysis and Fos immunohistochemistry for the estimation of dopamine neurotransmission in the rat caudate-putamen.Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment.Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue.Adenosine A2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas.Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
P50
Q28258352-EF9CDCCB-8641-4150-AD70-89B571181732Q28283008-5B6740A8-6C31-4ACA-A849-B2EB29CA485AQ35489240-01D1794C-6093-42E9-AFDD-32F3B7F09239Q36218699-64A9A317-0079-4D7B-BD16-F795C84E83BDQ36581230-B352918C-7A8B-4267-B23D-3226811092B4Q37201154-D7A6CA8A-C1D0-43F4-88CF-A77BB8F8D619Q37627259-42774B61-1A12-4E7A-92B2-9503B2E4E475Q37781372-683744B1-3DA7-4FD4-90D7-EBF63309D669Q38169996-8346E5D9-7CFA-41FE-8171-A6BBF446D136Q38200930-F54D7ECA-0048-4B67-B5A9-2F6FF302504CQ39008496-A36BFC59-9926-43A0-A79B-42FC4544CD56Q42446212-ED39BBE9-B857-47E1-A97A-FD76778EE63DQ42491104-5DE52FA1-5ACA-49CD-87BA-F898465CF57EQ43069227-1AB87AC3-4203-4009-94A6-428D86F9A602Q43232822-3D891EA6-9C54-4377-A2BF-5D886A1AA4F8Q43696891-40AC26A7-D9F4-46C1-BE13-82A25CAC12ACQ43959920-4B903DBD-2315-4AD8-BF09-54B5BEEF47BCQ44050773-B45C55D3-A129-43D4-8D0D-414536482566Q44324438-375BC9A1-5EC2-4ED6-A972-8A0897BA1A88Q44515045-26F4D0B7-E91D-429B-A08E-EBB187C33228Q44760113-A3DE130B-D9D3-49D3-9F14-7D188C5502F9Q45228276-7656D7E9-C194-468A-A1AD-28820DFFAAD2Q46041503-CBFB2159-1A01-4C16-B13A-B8EFAC2047EFQ46120293-A3157654-CE25-487E-9919-BBDD607ACD0BQ46425088-EC7B3F90-DE24-4171-B7CA-2B636B416DD4Q46445616-574A5424-F050-4F39-891E-F6C5AD2B5D6CQ46628076-DD0DC51B-86BB-4C5C-B928-BE012BF60556Q46803036-D58C0018-0912-4540-B6F2-D9E6A6920CD2Q48112379-80DC2A70-4E52-466E-9E15-48F6CB6803DAQ48155603-4E875C33-2B3D-43C7-8F4B-55CDBB5E4321Q48179724-3FAF1060-86ED-4352-847A-3E352A3C8EDAQ48254192-1FFCF82E-0971-4FB0-8573-E47E692F366AQ48279278-0485C4A3-0BCB-4C4D-836E-6C9223DC53E0Q48308273-63464CE5-BCBE-4721-8C70-57241E7D70B9Q48316323-51473C14-4ED6-4A53-8F04-ADBF9DFADB1FQ48442735-A55BDAEB-A9B2-430D-9097-BE1F74C171E7Q48580837-E6D147E8-D9DC-47EB-B191-0C0590B5DE13Q48657448-89AE8609-31A3-47A6-AC6A-06F104B0852AQ48684664-756BD14B-C42C-4908-9267-73D2A3565B0FQ48795844-6AD9552C-B589-439B-824A-641708A05184
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Annalisa Pinna
@ast
Annalisa Pinna
@en
Annalisa Pinna
@es
Annalisa Pinna
@nl
type
label
Annalisa Pinna
@ast
Annalisa Pinna
@en
Annalisa Pinna
@es
Annalisa Pinna
@nl
altLabel
Pinna A
@en
prefLabel
Annalisa Pinna
@ast
Annalisa Pinna
@en
Annalisa Pinna
@es
Annalisa Pinna
@nl
P1053
J-4212-2012
P106
P1153
7005163509
P21
P2798
P31
P3829
P4012
P496
0000-0002-4911-1735